EUVIMEDOpdag EUVIMED
Multizentrische StudieOpen access · CC BY 4.0

Impact of duration of chronic migraine on long‐term effectiveness of monoclonal antibodies targeting the calcitonin gene‐related peptide pathway—A real‐world study

Raffaele Ornello iD, Francesca Baldini, Agnese Onofri, Chiara Rosignoli, Federico De Santis iD, Andrea Burgalassi, Alberto Chiarugi, Pierangelo Geppetti, Simona Sacco, Luigi Francesco Iannone

Headache: The Journal of Head and Face Pain · 2025

DOI: 10.1111/head.14788 ↗

At a glance

Multizentrische Studie in Headache: The Journal of Head and Face Pain, 2025. Written by Raffaele Ornello and 9 co-authors. Institution: Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy. Major MEDLINE topics: Migraine Disorders, Calcitonin Gene-Related Peptide, Antibodies, Monoclonal, Calcitonin Gene-Related Peptide Receptor Antagonists. Cited 6 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

We assessed whether the effectiveness of monoclonal antibodies (mAbs) targeting the calcitonin gene‐related peptide (CGRP) pathway changes according to the duration of chronic migraine (CM) over 12 months.

Background

In most patients, CM is a progressive disease starting with episodic migraine. Longer CM duration might be associated with more difficult treatment, probably because the mechanisms underlying chronicization are strengthened. Therefore, early treatment of CM could lead to better outcomes compared with later treatment.

Methods

This cohort study included individuals with CM treated with anti‐CGRP mAbs in two tertiary headache centers from April 2019 to May 2023. The primary outcome included a change in monthly migraine days (MMDs) from baseline to the third trimester of treatment, 10–12 months. Secondary outcomes established whether response to anti‐CGRP mAbs has a more rapid onset in individuals with shorter CM duration compared with longer duration; they included change in MMDs, monthly headache days (MHDs), and days and number of intakes of acute medication during each trimester compared to baseline. Additional outcomes included persisting MMDs, MHDs, and days and number of intakes of acute medication during each trimester of treatment. Patients were compared across tertiles of the overall CM duration.

Results

The study included 335 individuals with CM, with a median (interquartile range [IQR]) age of 48 (39–57) years; 270 (80.6%) were women. Patients in the highest tertile of CM duration (aged 18–60 years) were older than patients in the lower duration tertiles (0–7 years and 8–18 years, respectively), with a median (IQR) age of 56 (48–64) years compared with 42 (31–50) years, and 48 (39–56)years, respectively ( p = 0.025); however, this difference was likely due to a correlation between age and disease duration. The change in MMDs from baseline to the last trimester of treatment (10–12 months) was comparable across tertiles of CM duration (median [IQR] −12 [−18 to −5] days, −12 [−17 to −6] days, and −12 [−18 to −4] days; p = 0.946). No difference emerged in secondary outcomes, suggesting a similar time to onset of anti‐CGRP mAbs effect across all tertiles of CM duration.

Conclusions

Our data showed that anti‐CGRP mAbs are effective and have a rapid onset of action in CM regardless of disease duration.

Subjects

MeSH terms (MEDLINE)

Migraine DisordersCalcitonin Gene-Related PeptideAntibodies, MonoclonalCalcitonin Gene-Related Peptide Receptor AntagonistsOutcome Assessment, Health CareHumansAdultFemaleMaleMiddle AgedChronic DiseaseCohort StudiesTime FactorsYoung Adult

Author keywords

chronic migraineerenumabfremanezumabgalcanezumabreal‐world evidence

Substances

Calcitonin Gene-Related PeptideAntibodies, MonoclonalCalcitonin Gene-Related Peptide Receptor Antagonists

Authors and institutions

  • Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Department of Clinical Medicine, Public Health, Life and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
  • Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
  • Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy.
  • Department of Pathobiology, School of Dentistry, New York University, New York, New York, USA.

ORCID profiles: Raffaele Ornello, Federico De Santis

Cite

APA

Ornello, R., Baldini, F., Onofri, A., Rosignoli, C., De Santis, F., Burgalassi, A., Chiarugi, A., Geppetti, P., Sacco, S., & Iannone, L. F. (2025). Impact of duration of chronic migraine on long‐term effectiveness of monoclonal antibodies targeting the calcitonin gene‐related peptide pathway—A real‐world study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14788

Vancouver

Ornello R, Baldini F, Onofri A, Rosignoli C, De Santis F, Burgalassi A, et al. Impact of duration of chronic migraine on long‐term effectiveness of monoclonal antibodies targeting the calcitonin gene‐related peptide pathway—A real‐world study. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14788

BibTeX
@article{Ornello2025,
  author = {Ornello, Raffaele and Baldini, Francesca and Onofri, Agnese and Rosignoli, Chiara and De Santis, Federico and Burgalassi, Andrea and Chiarugi, Alberto and Geppetti, Pierangelo and Sacco, Simona and Iannone, Luigi Francesco},
  title = {Impact of duration of chronic migraine on long‐term effectiveness of monoclonal antibodies targeting the calcitonin gene‐related peptide pathway—A real‐world study},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  doi = {10.1111/head.14788}
}
Start for free →